Helen Torley, PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC. (HALO), sold 57,377 shares at $68.51 ($2.2M) on 2025-12-01, disclosed to the SEC on 2025-12-01.
Scheduled sale ($2.2M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 25,000 | $0 | 0.0% |
| 2 | $68.51 | 10,406 | $713K | 32.0% |
| 3 | $68.51 | 10,406 | $713K | 32.0% |
| 4 | $69.44 | 5,402 | $375K | 16.8% |
| 5 | $69.44 | 5,402 | $375K | 16.8% |
| 6 | $70.36 | 500 |
| $35K |
| 1.6% |
| 7 | $71.60 | 261 | $19K | 0.8% |
| Total | $38.86 avg | 57,377 | $2.2M | 100% |
| Filing → |
| HALO | SELL | 2026-08-19 | $6.3M | — | Filing → |
| HALO | SELL | 2026-07-09 | $153K | — | Filing → |
| HALO | SELL | 2026-06-03 | $3.4M | — | Filing → |